• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Louisiana prisoners may get non-FDA-approved naltrexone implant

May 8, 2019 By Nancy Crotti

This article has been updated to clarify the BioCorRx’s role in the program.

BioCorRx updated logoThe Louisiana Department of Corrections is working with BioCorRx (OTC:BICX) to offer soon-to-be-released inmates an opioid addiction treatment implant that has not been approved by the FDA.

The implant, which contains a compounded form of naltrexone, is one of several medication-assisted options being offered to 10 inmates as part of BioCoRx’s recovery program, according to the Anaheim, Calif.-based company. That program typically includes the company’s proprietary cognitive behavioral therapy, peer support and patient tracking in addition to the multi-month naltrexone implant. Inmates’ participation must be approved by prison medical staff.

The voluntary program has drawn praise from corrections officials and concern from prisoner advocates and some medical professionals, according to a report in The Advocate, a Baton Rouge, La. newspaper.

Dr. Jody Rich, co-director of the Rhode Island-based nonprofit The Center for Prisoner Health and Human Rights, wondered why the Louisiana Department of Corrections would offer prisoners an implant that does not have FDA approval.

“Consent is always problematic (in prison),” Rich told The Advocate. “The least we can do is the gold standard of medical approval … to make sure they’re safe.”

The naltrexone implant is formulated by a compounding pharmacy, which is governed by FDA regulations, according to BioCoRx. The company said it is participating in the Louisiana program to demonstrate the effectiveness of its program for those with alcohol and/or opioid use disorders while illustrating the cost and societal benefit of using the program in lieu of incarceration.

Naltrexone implants have been used worldwide for about 20 years in countless individuals, according to the BioCoRxcompany. The FDA has approved naltrexone for administration orally or by injection.

“Compounded implants have been used in the U.S. under state and federal compounding guidance for more than (two) decades,” a company spokeswoman said in an email to Drug Delivery Business. “This has been well established. Furthermore, naltrexone has been approved several times in various forms by the FDA.”

“We are passionate about individuals overcoming addiction and have seen demonstrated results from our BioCorRx recovery program nationwide,” said  BioCorRx president & CEO Brady Granier in a news release announcing the prison pilot program. “We are proud to partner with the Louisiana Department of Corrections to showcase the effectiveness of sustained-release naltrexone combined with structured behavioral therapy and peer support.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Research & Development, Uncategorized Tagged With: BioCorRx, National Institutes of Health, nationalinstituteondrugabuse

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS